In March 2025, Anses issued a warning strongly advising against the consumption of dietary supplements containing the plant Garcinia cambogia Dsr. or preparations based on Garcinia cambogia due to the risks of severe adverse effects associated with its consumption. The decree of April 17, 2025, suspends in France for one year the importation, introduction, and marketing, whether for a fee or free of charge, of dietary supplements containing the plant Garcinia cambogia Desr and all preparations derived from this plant.
Following an exploration of potential regulatory pathways for cannabidiol (CBD) products by an internal Food and Drug Administration (FDA) working group, the FDA concluded on January 26, 2023, that a new regulatory pathway for CBD is needed to provide the regulatory oversight necessary to manage risk. The Agency is prepared to work with Congress on this issue.
Français